EGFR expression has been documented in canine soft tissue sarcomas (STS), and the pharmacokinetics of gefitinib were also previously characterized in canine, supporting the feasibility of a relevant and comparative therapeutic study in this species [40,41]. Here, EGFR is linked to telomere syndrome.